Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $41.25.
Several research firms recently issued reports on RCUS. Truist Financial reiterated a “buy” rating and issued a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Mizuho dropped their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, January 30th.
Read Our Latest Analysis on Arcus Biosciences
Insiders Place Their Bets
Institutional Trading of Arcus Biosciences
Hedge funds have recently made changes to their positions in the business. AE Wealth Management LLC acquired a new stake in Arcus Biosciences during the 3rd quarter worth approximately $410,000. Mach 1 Financial Group LLC purchased a new stake in shares of Arcus Biosciences during the third quarter worth $409,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Arcus Biosciences by 20.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,732 shares of the company’s stock valued at $246,000 after acquiring an additional 2,289 shares in the last quarter. BluePath Capital Management LLC acquired a new position in Arcus Biosciences during the 3rd quarter worth $28,000. Finally, Strs Ohio acquired a new position in Arcus Biosciences during the 3rd quarter worth $43,000. Institutional investors and hedge funds own 92.89% of the company’s stock.
Arcus Biosciences Stock Performance
Shares of RCUS stock opened at $15.55 on Friday. Arcus Biosciences has a fifty-two week low of $12.95 and a fifty-two week high of $25.47. The firm has a market capitalization of $1.41 billion, a PE ratio of -3.75 and a beta of 0.81. The stock’s 50-day simple moving average is $17.48 and its 200-day simple moving average is $16.61.
Arcus Biosciences (NYSE:RCUS – Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.01. The company had revenue of $31.00 million for the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. Arcus Biosciences’s quarterly revenue was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.93) EPS. Sell-side analysts forecast that Arcus Biosciences will post -3.59 earnings per share for the current year.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Recommended Stories
- Five stocks we like better than Arcus Biosciences
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 4/22 – 4/26
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Stocks Leading the U.S. Agriculture Comeback
- The How And Why of Investing in Oil Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.